X

Trial Profile

A Phase 3 Trial of TransCon hGH (lonapegsomatropin) for the Treatment for Pediatric Growth Hormone Deficiency (GHD)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lonapegsomatropin (Primary)
Indications Somatotropin deficiency
Focus Registrational; Therapeutic Use
Acronyms riGHt
Sponsors Ascendis Pharma

Most Recent Events

07 Jan 2024 Status changed from recruiting to active, no longer recruiting, as per Ascendis Pharma media release.
10 Aug 2022 According to an Ascendis Pharma media release, enrollment completion in the trial expected by the end of 2022.
25 Aug 2021 Status changed from planning to recruiting according to an Ascendis Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com